Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888956 | 0.78 | PRCP (0.44) | PRCP | |
| SCHEMBL889123 | 0.74 | CYP3A4 (0.40) | CYP3A4CYP2C9JAK3NR1I2ABCB11 | |
| SCHEMBL10120777 | 0.72 | CYP3A4 (0.44) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL889124 | 0.72 | BRAF (0.38) | CYP3A4CYP2C9JAK3NR1I2ABCB11 | |
| SCHEMBL12772532 | 0.72 | CYP3A4 (0.47) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL16501637 | 0.71 | CYP3A4 (0.46) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12558311 | 0.71 | CYP3A4 (0.50) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL15871289 | 0.71 | CYP3A4 (0.49) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL23247507 | 0.70 | OPRD1 (0.44) | CYP3A4CYP2C9PRCP | |
| SCHEMBL12755265 | 0.70 | XPNPEP1 (0.44) | XPNPEP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | CYP3A4 241/4885CYP2C9 394/4885JAK3 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.